{"id":408064,"date":"2019-08-16T00:00:00","date_gmt":"2019-08-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2019-biopharma-asthma-access-and-reimbursement-us-2019\/"},"modified":"2026-05-06T11:22:25","modified_gmt":"2026-05-06T11:22:25","slug":"acreim0002-2019-biopharma-asthma-access-and-reimbursement-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2019-biopharma-asthma-access-and-reimbursement-us-2019\/","title":{"rendered":"Asthma | Access and Reimbursement | US | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The dynamics within the LABA\/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA\/ICS FDCs (e.g., GlaxoSmithKline\u2019s Advair, AstraZeneca\u2019s Symbicort) will likely diminish as new generic \/ branded generic agents continue to launch over the next several years. In addition, the entrance of LABA\/LAMA\/ICS FDCs could create uptake challenges for Boehringer Ingelheim\u2019s Spiriva. Finally, the launch of novel biologics and potentially an oral therapy will fuel competition and pricing pressure in the severe refractory segment of the asthma market. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current and emerging asthma agents will be faced with increasing challenges to gain favorable formulary position and market uptake.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>Which key asthma therapies (e.g., Advair, Symbicort, GlaxoSmithKline\u2019s Nucala, Sanofi \/ Regeneron\u2019s Dupixent) receive favorable formulary placement, and how do payers manage the use and costs of these therapies?<\/li>\n<li>How do reimbursement restrictions affect physicians\u2019 prescribing of LABA\/ICS FDCs, Spiriva, and biologics to their asthma patients?<\/li>\n<li>How do payers \/ physicians expect current and emerging branded and generic \/ branded generic versions of market-leading LABA\/ICS FDCs (e.g., AB-rated generics of Advair and Symbicort) to impact access \/ prescribing to current branded therapies?<\/li>\n<li>How do physicians anticipate using emerging biologics (e.g., Amgen \/ AstraZeneca\u2019s tezepelumab), oral agents (i.e., Novartis\u2019s fevipiprant), and LABA\/LAMA\/ICS FDCs (i.e., GlaxoSmithKline\u2019s Trelegy), and how do payers expect to cover these therapies on commercial plans at various price points?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement <\/em>provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.<\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary Research:<\/strong> Survey of 100 U.S. pulmonologists and allergists Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs \/ MDs)<\/p>\n<p><strong>Key Drugs Covered:<\/strong> Advair, Breo, Symbicort, Dulera, AirDuo, Wixela, Spiriva, Xolair, Nucala, Cinqair, Fasenra, Dupixent, Trelegy, tezepelumab, fevipiprant, indacaterol \/ mometasone, Trelegy<\/p>\n<p><strong>Content Highlights:<\/strong><\/p>\n<ul>\n<li>Reimbursement and contracting<\/li>\n<li>Access and prescribing<\/li>\n<li>Special topics<\/li>\n<li>Opportunities and challenges for emerging therapies<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-408064","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/408064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/408064\/revisions"}],"predecessor-version":[{"id":576619,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/408064\/revisions\/576619"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=408064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}